Gilead Reports Results of Veklury (remdesivir) in P-III Trial for the Treatment of COVID-19

 Gilead Reports Results of Veklury (remdesivir) in P-III Trial for the Treatment of COVID-19

Shots:

  • The P-III trial evaluates the efficacy & safety of a 3-day course of Veklury (IV) vs PBO in a ratio (1:1) in 562 non-hospitalized patients ≥aged 12yrs. with COVID-19 who are at high risk for disease progression. The results will be presented at IDWeek 2021
  • The results showed an 87% & 81% reduction in risk for composite 1EPs & 2EPs of COVID-19 related hospitalization or all-cause death @28Day (0.7% vs 5.3%) & (1.6% vs 8.3%), no new safety signals & no deaths were observed
  • Veklury is a nucleotide analog with broad-spectrum antiviral activity both in vitro/ in vivo in animal models against multiple emerging viral pathogens. The company plans to file an IND with the FDA in early 2022

Click here to­ read full press release/ article | Ref: Gilead | Image: Reuters

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post